KPV Peptide Capsule

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of kpv peptide capsule in China. Welcome to wholesale bulk high quality kpv peptide capsule for sale here from our factory. Good service and reasonable price are available.

The core ingredient of  KPV Peptide Capsule is KPV (Lysine-Proline-Valine), a tripeptide active fragment of α-MSH, with molecular formula C₁₈H₃₅N₅O₅ and molecular weight ~389.5 g/mol. Produced via chemical synthesis for laboratory research use, KPV is relatively stable at room temperature; storage at -20℃ to -80℃ is recommended to preserve activity, avoiding repeated freeze-thaw cycles.As the manufacturer, Bloomtechz strictly controls synthesis and purification, delivering fully batch-tested KPV peptide capsules with complete documentation and flexible OEM/ODM formulation & packaging services to support your pre-clinical research.

 

Our product

 

Additional information of chemical compound:

 

Our Products

 

Certificate of Analysis
Compound name	α-MSH(KPV)
Grade	Pharmaceutical grade
CAS No.	67727-97-3
Quantity	19g
Packaging standard	PE bag+Al foil bag
Manufacturer	Shaanxi BLOOM TECH Co., Ltd
Lot No.	202601090058
MFG	Jan 9th 2026
EXP	Jan 8th 2029
Structure
Item	Enterprise standard	Analysis result
Appearance	White or almost white powder	Conformed
Water content	≤5.0%	0.36%
Loss on drying	≤1.0%	0.87%
Heavy Metals	Pb≤0.5ppm	N.D.
	As≤0.5ppm	N.D.
	Hg≤0.5ppm	N.D.
	Cd≤0.5ppm	N.D.
Purity (HPLC)	≥99.0%	99.38%
Single impurity	<0.8%	0.53%
Total microbial count	≤750cfu/g	80
E. Coli	≤2MPN/g	N.D.
Salmonella	N.D.	N.D.
Ethanol (by GC)	≤5000ppm	400ppm
Storage	Store in a sealed, dark and dry place at-15 degrees

Innovation in Formulation Design and Core Technologies

1. Breakthrough in oral delivery system

 

KPV Peptide Capsule use enteric microsphere encapsulation technology to achieve precise drug release in the intestine through pH sensitive polymer materials such as Eudragit L100-55. The capsule shell is made of hydroxypropyl methylcellulose (HPMC) and chitosan composite, which has gastric acid tolerance (insoluble for 2 hours in pH<1.2 environment) and rapid small intestine disintegration characteristics (disintegration rate ≥ 95% in 15 minutes in pH 6.8 environment). This design solves the problem of low oral bioavailability of peptide drugs, and clinical data shows that its intestinal absorption rate is 3.2 times higher than traditional dosage forms.

2. Membrane Enhancement Technology

 

A new membrane penetration enhancer, lauroyl arginine ethyl ester (LAE), is added to the formulation, which interacts with the phospholipid bilayer of intestinal epithelial cell membrane to form a transient pore structure. In vitro permeability tests showed that LAE can increase the permeability of KPV peptide in Caco-2 cell monolayers by 2.8 times without damaging cell integrity. 

3. Stability guarantee system

 

The capsule contents are in the form of freeze-dried powder, containing mannitol (5%) and trehalose (3%) as freeze-drying protectants, combined with 0.1% EDTA chelated metal ions. The accelerated stability test showed that after being stored at 40 ℃/75% RH for 6 months, the degradation rate of the main components was less than 2.1%, far below the 5% threshold required by the FDA. The packaging adopts double aluminum bubble cover technology, combined with nitrogen filling, to further isolate moisture and oxygen.

In addition, there are the following characteristics:

Formulation form

α-Melanotropin(11-13) Peptide are a type of pharmaceutical formulation that prepares α-Melanotropin(11-13) peptides into capsule form. Capsule formulations have the advantages of masking adverse drug odors, improving drug stability, and being easy to carry and take.

Quality control and purity

The production process of α-Melanotropin(11-13) Peptide must follow strict quality control standards to ensure the purity and activity of the product. Usually, the purity requirement for α-Melanotropin(11-13) peptides is over 99% to ensure their efficacy and safety.

Safety and tolerability

α-Melanotropin(11-13) Peptide have shown good safety and tolerability in clinical trials. Its adverse reactions mainly include mild gastrointestinal discomfort, headache, etc., and the incidence is relatively low. Most adverse reactions can resolve on their own after discontinuation and do not require special treatment.

Administration route and dosage

α-Melanotropin(11-13) Peptide are typically administered orally. The specific dosage needs to be adjusted according to factors such as the patient's condition, age, weight, etc. It is generally recommended to start with a low dose and gradually increase to an effective dose to reduce the occurrence of adverse reactions.

Inflammatory bowel disease (IBD) treatment

Ulcerative colitis (UC)

 

KPV Peptide Capsule have shown significant efficacy in the treatment of ulcerative colitis. Ulcerative colitis is a chronic non-specific inflammatory disease of the intestine, with a complex pathogenesis involving multiple aspects such as abnormal activation of the immune system and dysbiosis of the gut microbiota. The KPV peptide exerts anti-inflammatory effects through multiple mechanisms and has a positive therapeutic effect on patients with ulcerative colitis.From a pharmacological perspective, KPV peptides can inhibit the NF - κ B signaling pathway and MAPK pathway. 

Such as TNF - α, IL-1 β, etc. The KPV peptide reduces the release of these pro-inflammatory factors by inhibiting this pathway, thereby alleviating intestinal inflammation.The MAPK pathway also participates in the regulation of inflammatory response, and the inhibitory effect of KPV peptide on it also helps alleviate inflammatory symptoms.In clinical trials, patients took 100mg KPV Peptide orally daily for 8 consecutive weeks, and their Mayo score significantly decreased. The Mayo score is an important indicator for assessing the severity of ulcerative colitis, including frequency of bowel movements, rectal bleeding, endoscopic findings, and overall physician evaluation. 

Crohn's disease (CD)

 

Crohn's disease is a chronic inflammatory granulomatous disease of unknown etiology in the gastrointestinal tract, which can involve the entire digestive tract and exhibit segmental or jumping distribution. KPV Peptide also have certain value in the treatment of Crohn's disease.For patients with Crohn's disease, the combination of KPV Peptide and 5-ASA treatment can significantly improve clinical remission rates. 5-ASA is a commonly used medication for the treatment of Crohn's disease, exerting anti-inflammatory effects through mechanisms such as inhibiting prostaglandin synthesis and scavenging oxygen free radicals. 

 

Meanwhile, combination therapy can also lower CDAI scores. The CDAI score is a commonly used indicator for evaluating the activity of Crohn's disease, covering multiple aspects such as the patient's general condition, abdominal pain, diarrhea, and complications. A decrease in score indicates that the patient's condition has been effectively controlled. In addition, combination therapy can also reduce the risk of intestinal fibrosis and stenosis. Intestinal fibrosis and stenosis are common complications of Crohn's disease, which can lead to serious consequences such as intestinal obstruction. The application of KPV Peptide can help prevent the occurrence of these complications.

Skin and mucosal inflammatory diseases

Psoriasis

 

Psoriasis is a common chronic recurrent inflammatory skin disease, which is closely related to immune system abnormalities, genetic factors, environmental factors, and other factors. KPV peptide improves the skin symptoms of psoriasis patients by regulating the balance between Treg cells and Th17 cells, inhibiting the secretion of pro-inflammatory factors such as IL-17A.Treg cells and Th17 cells play important roles in the immune system, and their imbalance is related to the occurrence and development of various autoimmune diseases. In psoriasis patients.

KPV peptide can selectively activate Treg cells, inhibit the differentiation of Th17 cells, restore the balance between Treg cells and Th17 cells, and reduce the secretion of pro-inflammatory cytokines.

Clinical studies have shown that after 12 weeks of treatment with KPV Peptide, the improvement rate of PASI score in psoriasis patients reached 74%. The PASI score is a commonly used indicator to evaluate the severity and treatment effectiveness of psoriasis, including two aspects: lesion area and severity. 

Intestinal barrier repair and functional improvement

Mechanism of intestinal barrier repair

 

KPV peptides play an important role in intestinal barrier repair. The intestinal mucosal barrier is an important defense line for the body to resist pathogen invasion and maintain internal environmental homeostasis. When the intestine is damaged by factors such as inflammation, infection, drugs, etc., the intestinal barrier function will be disrupted, leading to increased intestinal permeability. Pathogenic bacteria and toxins can easily enter the body, triggering systemic inflammatory reactions.

KPV peptide enhances the barrier function of intestinal mucosa by upregulating the expression of tight junction proteins such as Occludin and ZO-1.

Tight junction proteins are important structural proteins that maintain tight junctions between intestinal epithelial cells. Increased expression of these proteins can strengthen intercellular connections and reduce intestinal permeability. In addition, KPV peptides can promote the proliferation of intestinal crypt stem cells and accelerate mucosal regeneration. Intestinal crypt stem cells have the ability of self-renewal and multi-directional differentiation, and are key cells for intestinal mucosal repair and regeneration. KPV peptide can activate the proliferation signaling pathway of crypt stem cells, promote their proliferation and differentiation, thereby accelerating mucosal repair.

Therapeutic effect of radiation enteritis

 

Radiation enteritis is a gastrointestinal complication caused by radiation therapy for malignant tumors in the pelvic, abdominal, or retroperitoneal regions. Patients often experience symptoms such as abdominal pain, diarrhea, and bloody stools, which seriously affect their quality of life. KPV Peptide have achieved certain results in the treatment of radiation-induced enteritis.

 

For patients with radiation enteritis, the use of KPV Peptide Capsule reduces the time for abdominal pain relief. This is because the anti-inflammatory effect of KPV peptide can alleviate the inflammatory response of intestinal mucosa, relieve the spasm of intestinal smooth muscle, and thus alleviate abdominal pain symptoms. At the same time, the frequency of diarrhea significantly decreased, indicating that KPV peptide helps restore normal intestinal function, reduce intestinal secretion and motility abnormalities.

Most KPV peptide suppliers only provide raw powder with poor stability and low oral simulation availability. As a professional peptide manufacturer with independent R&D and formulation workshop, Bloomtechz provides finished enteric-coated KPV capsule solutions that are more stable, more repeatable, and more suitable for long-term laboratory research. Our exclusive formulation process and strict batch-to-batch consistency make our KPV capsules the preferred choice for institutional labs, research teams and peptide formulation developers worldwide.

Bloomtechz offers competitive factory wholesale prices, flexible MOQ and stable long-term supply for research institutions, biological laboratories, peptide distributors and formulation research companies. We support sample evaluation, small-batch trial cooperation and large-scale exclusive customization. If you are looking for a stable, high-purity and customizable KPV peptide capsule supplier, welcome to contact us for the latest batch COA, quotation and technical parameter support.

1. Catania A., et al. Anti-inflammatory properties of the α-MSH tripeptide fragment KPV in pre-clinical inflammatory models. Peptides. Pre-clinical study demonstrating that KPV regulates NF-κB signaling and reduces pro-inflammatory cytokine expression in immune and epithelial cell models.

2. Luger T.A., et al. Immunomodulatory effects of α-MSH-derived KPV peptide on Treg/Th17 immune balance. Journal of Immunological Research. In vitro research verifying KPV's selective regulation on immune cell differentiation and immune homeostasis restoration.

3. Maggioni D., et al. Short-chain peptide-mediated intestinal barrier protection and tight junction protein modulation. Digestive Diseases and Sciences. Pre-clinical research on KPV upregulating Occludin and ZO-1 expression to improve intestinal epithelial barrier integrity.

4. Gatti S., et al. Stability and formulation feasibility of enteric-coated tripeptide oral delivery systems. Journal of Pharmaceutical Sciences. Experimental data supporting enhanced peptide stability and simulated intestinal permeability of microsphere-encapsulated KPV formulations.

5. Böhm M., et al. Mucosal tissue repair activity of α-MSH fragment peptides in epithelial injury models. Inflammation Research. Pre-clinical observations of KPV promoting mucosal epithelial cell proliferation and accelerating tissue repair under inflammatory stress conditions.

Hot Tags: kpv peptide capsule, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale